Compare · GILD vs QNCX
GILD vs QNCX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.26B, about 9837.4x QNCX ($15.8M).
- Over the past year, GILD is up 16.7% and QNCX is down 93.3% - GILD leads by 109.9 points.
- GILD has been more active in the news (17 items in the past 4 weeks vs 9 for QNCX).
- GILD has more recent analyst coverage (25 ratings vs 4 for QNCX).
- Company
- Gilead Sciences Inc.
- Quince Therapeutics Inc.
- Price
- $125.05+0.17%
- $0.97+4.56%
- Market cap
- $155.26B
- $15.8M
- 1M return
- -4.14%
- -9.62%
- 1Y return
- +16.66%
- -93.28%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2019
- News (4w)
- 17
- 9
- Recent ratings
- 25
- 4
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
Latest QNCX
- Cantor Fitzgerald initiated coverage on Quince Therapeutics with a new price target
- SEC Form 4 filed by Director Lamond David
- SEC Form 4 filed by Director Senner Christopher J.
- SEC Form 4 filed by Chief Corp. Affairs Officer Roberts Brigette
- SEC Form 3 filed by new insider Roberts Brigette
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form D filed by Quince Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.